CVS Health Corp (NYSE: CVS)’s stock price has plunge by 0.92relation to previous closing price of 73.90. Nevertheless, the company has seen a -6.49% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-05 that The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock’s price.
Is It Worth Investing in CVS Health Corp (NYSE: CVS) Right Now?
The price-to-earnings ratio for CVS Health Corp (NYSE: CVS) is above average at 11.53x, Company’s 36-month beta value is 0.52.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 5 as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for CVS is 1.26B, and currently, short sellers hold a 1.48% ratio of that floaft. The average trading volume of CVS on April 08, 2024 was 11.28M shares.
CVS’s Market Performance
CVS stock saw an increase of -6.49% in the past week, with a monthly gain of 0.32% and a quarterly increase of -7.37%. The volatility ratio for the week is 2.29%, and the volatility levels for the last 30 days are 2.03% for CVS Health Corp (CVS). The simple moving average for the past 20 days is -3.15% for CVS’s stock, with a 2.66% simple moving average for the past 200 days.
Analysts’ Opinion of CVS
Many brokerage firms have already submitted their reports for CVS stocks, with Barclays repeating the rating for CVS by listing it as a “Equal Weight.” The predicted price for CVS in the upcoming period, according to Barclays is $78 based on the research report published on March 06, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see CVS reach a price target of $88. The rating they have provided for CVS stocks is “Outperform” according to the report published on February 26th, 2024.
HSBC Securities gave a rating of “Buy” to CVS, setting the target price at $94 in the report published on December 22nd of the previous year.
CVS Trading at -1.65% from the 50-Day Moving Average
After a stumble in the market that brought CVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.41% of loss for the given period.
Volatility was left at 2.03%, however, over the last 30 days, the volatility rate increased by 2.29%, as shares surge +0.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.53% upper at present.
During the last 5 trading sessions, CVS fell by -6.49%, which changed the moving average for the period of 200-days by +8.61% in comparison to the 20-day moving average, which settled at $77.02. In addition, CVS Health Corp saw -5.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVS starting from Shah Prem S, who sale 29,473 shares at the price of $76.95 back on Feb 16 ’24. After this action, Shah Prem S now owns 39,765 shares of CVS Health Corp, valued at $2,267,947 using the latest closing price.
LUDWIG EDWARD J, the Director of CVS Health Corp, purchase 2,000 shares at $70.47 during a trade that took place back on Nov 03 ’23, which means that LUDWIG EDWARD J is holding 20,630 shares at $140,930 based on the most recent closing price.
Stock Fundamentals for CVS
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- -0.03 for the gross margin
The net margin for CVS Health Corp stands at 0.02. The total capital return value is set at 0.08. Equity return is now at value 11.32, with 3.38 for asset returns.
Based on CVS Health Corp (CVS), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 1.04. The interest coverage ratio of the stock is 5.17.
Currently, EBITDA for the company is 19.05 billion with net debt to EBITDA at 3.98. When we switch over and look at the enterprise to sales, we see a ratio of 0.46. The receivables turnover for the company is 10.16for trailing twelve months and the total asset turnover is 1.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In a nutshell, CVS Health Corp (CVS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
